Skip to main navigation Skip to search Skip to main content

Tocilizumab improves the prognosis of covid-19 in patients with high il-6

  • Robert Flisiak
  • , Jerzy Jaroszewicz
  • , Magdalena Rogalska
  • , Tadeusz Łapiński
  • , Aleksandra Berkan-Kawińska
  • , Beata Bolewska
  • , Magdalena Tudrujek-Zdunek
  • , Dorota Kozielewicz
  • , Marta Rorat
  • , Piotr Leszczyński
  • , Krzysztof Kłos
  • , Justyna Kowalska
  • , Paweł Pabjan
  • , Anna Piekarska
  • , Iwona Mozer-Lisewska
  • , Krzysztof Tomasiewicz
  • , Małgorzata Pawłowska
  • , Krzysztof Simon
  • , Joanna Polanska
  • , Dorota Zarębska-Michaluk
  • Medical University of Białystok
  • Medical University of Silesia in Katowice
  • Medical University of Łódź
  • University of Medical Sciences Poznan
  • Medical University of Lublin
  • Nicolaus Copernicus University in Toruń
  • Wrocław Medical University
  • Gromkowski Regional Specialist Hospital in Wrocław
  • Szpital im. J. Strusia w Poznaniu
  • Wojskowy Instytut Medyczny
  • Medical University of Warsaw
  • Jan Kochanowski University in Kielce

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Despite direct viral effect, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab (TOC), a monoclonal antibody against IL-6 receptors, was considered as a possible therapeutic option. Patients were selected from the SARSTer database, containing 2332 individuals with COVID-19. Current study included 825 adult patients with moderate to severe course. Analysis was performed in 170 patients treated with TOC and 655 with an alternative medication. The end-points of treatment effectiveness were death rate, need for mechanical ventilation, and clinical improvement. Patients treated with TOC were balanced compared to non-TOC regarding gender, age, BMI, and prevalence of coexisting conditions. Significant effect of TOC on death was demonstrated in patients with baseline IL-6 > 100 pg/mL (hazard ratio [HR]: 0.21, 95% confidence interval [CI]: 0.08–0.57). The best effectiveness of TOC was achieved in patients with a combination of baseline IL-6 > 100 pg/mL and either SpO2 ≤ 90% (HR: 0.07) or requiring oxygen supplementation (HR: 0.18). Tocilizumab administration in COVID-19 reduces mortality and speeds up clinical improvement in patients with a baseline concentration of IL-6 > 100 pg/mL, particularly if they need oxygen supplementation owing to the lower value of SpO2 ≤ 90%.

Original languageEnglish
Article number1583
JournalJournal of Clinical Medicine
Volume10
Issue number8
DOIs
Publication statusPublished - 2 Apr 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • Interleukin-6
  • SARS-CoV-2
  • Therapy
  • Tocilizumab

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Tocilizumab improves the prognosis of covid-19 in patients with high il-6'. Together they form a unique fingerprint.

Cite this